Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T07:53:27.219Z Has data issue: false hasContentIssue false
  • English
  • Français

Behavioural and emotional implications of implantable cardioverter-defibrillators in the young and in athletes

Published online by Cambridge University Press:  13 January 2017

Brynn E. Dechert
Brynn E. Dechert*
Affiliation:
University of Michigan Congenital Heart Center, Ann Arbor, Michigan, United States of America
*
Correspondence to: B. E. Dechert, MSN, CPNP, FHRS, University of Michigan Congenital Heart Center, 1540 E. Hospital Dr, Ann Arbor, MI 48109, United States of America. Tel: 734-763-2191; Fax: 734-232-7175; E-mail: brynnd@umich.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Despite the life-saving capabilities of implantable cardioverter-defibrillators, they may have implications on behavioural and emotional well-being and have been shown to negatively affect patients’ psychosocial functioning. Children and CHD patients with these devices are at higher risk for complications, and therefore may have higher risk of psychosocial dysfunction including depression, anxiety, and a decrease in overall quality of life. In addition, these patients may be restricted from activities, which may also contribute to psychosocial dysfunction. Recommendations published in 2015 support a more liberal approach to athletic participation in this patient population compared with previous guidelines. Approaches to limit psychosocial dysfunction include education, minimisation of shocks, and psychosocial therapy. Psychosocial dysfunction should be assessed at each clinic visit, and information regarding intervention should be provided to patients and their families as needed. Psychosocial dysfunction may be debilitating, and healthcare providers should facilitate and support normal psychosocial function by offering resources as needed.

Keywords

Implantable cardioverter-defibrillatorpaediatricsCHDpsychosocial dysfunction
Type
Original Articles
Information
Cardiology in the Young , Volume 27 , Supplement S1: Sudden Cardiac Arrest in the Young: A Contemporary Perspective , January 2017 , pp. S138 - S142
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Webster, G, Panek, KA, Labella, M, et al. Psychiatric functioning and quality of life in young patients with cardiac rhythm devices. Pediatrics 2014; 133: e964–e972.Google Scholar
2. Koopman, HM, Wiersma-Vrijmoet, CM, Languis, JN, et al. Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter defibrillator. Pediatr Cardiol 2012; 33: 569–575.Google Scholar
3. Czosek, RJ, Bonney, WJ, Cassedy, A, et al. Impact of cardiac devices on the quality of life in pediatric patients. Circ Arrhythm Electrophysiol 2012; 5: 1064–1072.CrossRefGoogle ScholarPubMed
4. Sears, SF, St Amant, JB, Zeigler, V. Psychosocial considerations for children and young adolescents with implantable cardioverter defibrillators: an update. PACE 2009; 32: S80–S82.Google Scholar
5. Ingles, J, Sarina, T, Kasparian, N, Semsarian, C. Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults and genetic heart disease. Int J Cardiol 2013; 168: 3779–3784.CrossRefGoogle ScholarPubMed
6. Verkerk, AJ, Vermeer, AM, Smets, EM, et al. Quality of life in young adult patients with cardiogenetic condition receiving an ICD for primary prevention of sudden cardiac death. PACE 2015; 38: 870–877.CrossRefGoogle ScholarPubMed
7. Kamp, AN, Von Bergen, NH, Henrikson, CA, et al. Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr Cardiol 2013; 34: 1620–1627.CrossRefGoogle ScholarPubMed
8. Miyake, CY, Webster, G, Czosek, RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 2013; 6: 579–587.CrossRefGoogle ScholarPubMed
9. Von Bergen, NH, Atkins, DL, Dick, M II, et al. Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol 2011; 32: 399–405.Google Scholar
10. Alter, P, Waldhans, S, Plachta, E, Moosdorf, R, Grimm, W. Complications of implantable defibrillator therapy in 440 consecutive patients. PACE 2005; 28: 926–932.Google Scholar
11. De Witt, ES, Triedman, JK, Cecchin, F, et al. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. Circ Arrhythm Electrophysiol 2014; 7: 1057–1063.Google Scholar
12. Atallah, J, Erickson, CC, Cecchin, F, et al. Multi-institutional study of implantable defibrillator lead performance in children and young adults. Circulation 2013; 127: 2393–2402.CrossRefGoogle ScholarPubMed
13. Rahman, B, Macciocca, I, Sahhar, M, Kamberi, S, Connell, V, Duncan, RE. Adolescents with implantable cardioverter defibrillators: a patient and parent perspective. PACE 2012; 35: 62–72.Google Scholar
14. Zipes, DP, Link, MS, Ackerman, MJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 9: arrhythmias and conduction defects. Circulation 2015; 132: e315–e325.Google Scholar
15. Saeed, M, Hanna, I, Robotis, D, et al. Programming implantable cardioverter defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol 2014; 25: 52–59.Google Scholar
16. Wathens, MS, DeGroot, PJ, Sweeney, MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: pacing fast ventricular tachycardia reduces shock therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591–2596.Google Scholar
17. Roses-Noguer, F, Jarman, JW, Clague, JR, Till, J. Outcomes of defibrillator therapy in catecholeminergic polymorphic ventricular tachycardia. Heart Rhythm 2014; 11: 58–66.Google Scholar
18. Mastenbroek, MH, Pedersen, SS, van der Tweel, I, Doevendans, PA, Meine, M. Results of the ENHANCED implantable cardioverter defibrillator programming to reduce therapies and improve quality of life. Am J Cardiol 2016; 117: 596–604.Google Scholar
19. Irvine, J, Firestone, J, Ong, L, et al. A randomized controlled trial of cognitive behavior therapy tailored to psychological adaption to an implantable cardioverter defibrillator. Psychosomatic Medicine 2011; 73: 226–233.Google Scholar
20. Freedenberg, VA, Thomas, SA, Friedman, E. A pilot study of a mindfulness based stress reduction program in adolescents with implantable cardioverter defibrillators or pacemakers. Pediatr Cardiol 2014; 36: 786–795.Google Scholar